OncoMatch/Clinical Trials/NCT06926283
A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
Is NCT06926283 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies DXC008 for prostate cancer.
Treatment: DXC008 — This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC008 in patients with prostate cancer and other solid tumors such as Ewing sarcoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Tumor Agnostic
Sarcoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: standard treatment
Patients with various solid tumors who have failed standard treatment, including but not limited to progressive mCRPC
Cannot have received: XXX-targeted therapy
Ewing sarcoma: Prior treatment with XXX-targeted therapy (in Phase Ia clinical study only)
Cannot have received: XXX-targeted therapy or topoisomerase inhibitors
Other solid tumors: Prior treatment with XXX-targeted therapy or topoisomerase inhibitors (in Phase Ia clinical study only)
Lab requirements
Blood counts
ANC ≥ 1.5 × 10^9/L (prior use of G-CSF is allowed, but G-CSF use is not allowed within 7 days prior to the screening laboratory tests); Platelet count ≥100×10^9/L (platelet transfusion is not allowed within 7 days before the screening laboratory tests); HGB ≥ 90 g/L (RBC transfusion or recombinant human erythropoietin use is allowed; RBC transfusion is not allowed within 7 days prior to the screening laboratory tests).
Kidney function
Ccr ≥ 60 mL/min; or creatinine ≤ 1.5 × ULN; urinalysis results show protein urine ≤ 1 +. For subjects with urine protein ≥2+ in urinalysis during the screening period, a 24-hour urine protein quantification should be performed, and those with 24-hour urine protein quantification ≤1 g can be enrolled.
Liver function
Total bilirubin (TBIL) ≤1.5×ULN, except for subjects with congenital bilirubinemia, such as Gilbert syndrome (direct bilirubin ≤1.5×ULN); AST and ALT ≤ 3.0 × ULN. For patients with liver metastases, both AST and ALT ≤5×ULN.
Cardiac function
LVEF≥50%; QTcF interval ≥ 470 msec (QT interval must be corrected for heart rate using the Fridericia formula [QTcF]); Evidence of current clinically significant untreated arrhythmias, including clinically significant ECG abnormalities including second-degree (Mobitz Type II) or third-degree atrioventricular (AV) block; Within 6 months before screening, history of myocardial infarct, acute coronary syndrome (including unstable angina pectoris), coronary angioplasty or stent implantation, or bypass grafting; Class III or IV heart failure - as defined by the New York Heart Association Functional Classification; Uncontrolled severe hypertension: systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥ 100 mmHg.
Organ function of the subjects must meet the following requirements: Hematology: ANC ≥ 1.5 × 10^9/L... Liver function: TBIL ≤1.5×ULN... Renal function: Ccr ≥ 60 mL/min... Coagulation function: INR≤1.5. APTT or PT ≤ 1.5 × ULN. LVEF≥50%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06926283 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior XXX-targeted therapy, XXX-targeted therapy or topoisomerase inhibitors disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages